| PI4KB Inhibitor Ameliorates Exacerbation of Respiratory Diseases Caused by Rhinovirus Infection in Mice T Matsui, M Fujita, Y Ishibashi, TK Nomanbhoy, JS Rosenblum, ... A28. THE HOST DELIVERS, A1208-A1208, 2022 | | 2022 |
| 15-pgdh inhibitors S Herath, M Urbano, EK Kim, C Chen, Q Li, J Ayers, K Nakamura, X Zhu, ... US Patent App. 17/310,268, 2022 | | 2022 |
| 134. KRP-A218, an orally active and selective PI4KB inhibitor with broad-spectrum anti-rhinovirus activity, has potent therapeutic antiviral activity in vivo T Matsui, M Fujita, Y Ishibashi, T Nomanbhoy, JS Rosenblum, ... Open Forum Infectious Diseases 8 (Suppl 1), S82, 2021 | 3 | 2021 |
| Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1 alpha by Chemical Proteomics (vol 11, e0152934, 2016) ES Okerberg, A Hainley, H Brown, A Aban, S Alemayehu, A Shih, J Wu, ... PLOS ONE 12 (2), 2017 | | 2017 |
| Correction: Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1α by Chemical Proteomics ES Okerberg, A Hainley, H Brown, A Aban, S Alemayehu, A Shih, J Wu, ... Plos one 12 (2), e0172649, 2017 | | 2017 |
| Heterocyclic compounds Y Hu, ECK Lin, B Li, S Sidique, JS Rosenblum, OM Cociorva, KR Shreder, ... US Patent App. 15/121,282, 2017 | 7 | 2017 |
| ERK5 kinase activity is dispensable for cellular immune response and proliferation ECK Lin, CM Amantea, TK Nomanbhoy, H Weissig, J Ishiyama, Y Hu, ... Proceedings of the National Academy of Sciences 113 (42), 11865-11870, 2016 | 100 | 2016 |
| Chemoproteomic evaluation of target engagement by the cyclin-dependent kinase 4 and 6 inhibitor palbociclib correlates with cancer cell response TK Nomanbhoy, G Sharma, H Brown, J Wu, A Aban, S Vogeti, ... Biochemistry 55 (38), 5434-5441, 2016 | 32 | 2016 |
| A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation S Chillappagari, C Müller, P Mahavadi, A Guenther, L Nährlich, ... Journal of Cystic Fibrosis 15 (3), 325-331, 2016 | 12 | 2016 |
| Identification of a tumor specific, active-site mutation in casein kinase 1α by chemical proteomics ES Okerberg, A Hainley, H Brown, A Aban, S Alemayehu, A Shih, J Wu, ... PLoS One 11 (3), e0152934, 2016 | 11 | 2016 |
| Reinvestigating the role of ERK5: kinase activity is not required for cellular immune response or proliferation ECK Lin, CM Amantea, TK Nomanbhoy, H Weissig, J Ishiyama, Y Hu, ... BioRxiv, 038513, 2016 | 5 | 2016 |
| ATP acyl phosphate reactivity reveals native conformations of Hsp90 paralogs and inhibitor target engagement BE Nordin, Y Liu, A Aban, HE Brown, J Wu, AK Hainley, JS Rosenblum, ... Biochemistry 54 (19), 3024-3036, 2015 | 22 | 2015 |
| Profiling HSP90 inhibitors in cellular extracts on a mass spectrometry chemoproteomics platform TK Nomanbhoy, BE Nordin, J Rosenblum, Y Liu Cancer Research 74 (19_Supplement), 1789-1789, 2014 | | 2014 |
| Monitoring native p38α: MK2/3 complexes via trans delivery of an ATP acyl phosphate probe ES Okerberg, HE Brown, L Minimo, S Alemayehu, J Rosenblum, ... Journal of the American Chemical Society 136 (12), 4664-4669, 2014 | 14 | 2014 |
| Co-crystal structures of GSK3 beta and the 4-quinolone inhibitor AX9839: Specific and potent binding facilitated by a fluorine H-bond acceptor, an arginine stacking interaction … K Iwase, H Weissig, B Li, Q Li, O Cociorva, K Nakamura, M Nagasawa, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 247, 2014 | | 2014 |
| DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues EB Harstad, JS Rosenblum, MD Gorrell, WE Achanzar, L Minimo, J Wu, ... Regulatory Peptides 186, 26-35, 2013 | 18 | 2013 |
| Functional interrogation of kinases and other nucleotide-binding proteins JS Rosenblum, TK Nomanbhoy, JW Kozarich FEBS letters 587 (13), 1870-1877, 2013 | 24 | 2013 |
| KRP-104, a DPPIV inhibitor that uniquely matches extracellular target localisation with compound exposure, is a safe and effective candidate for type 2 diabetes T Ide, W Hori, JS Rosenblum, L Minimo, T Matsui, Y Kitamura, T Anraku, ... DIABETOLOGIA 55, S51-S51, 2012 | | 2012 |
| Synthesis and structure–activity relationship of (1-halo-2-naphthyl) carbamate-based inhibitors of KIAA1363 (NCEH1/AADACL1) KR Shreder, ECK Lin, J Wu, J Cajica, CM Amantea, Y Hu, E Okerberg, ... Bioorganic & medicinal chemistry letters 22 (17), 5748-5751, 2012 | 16 | 2012 |
| Synthesis and structure–activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β OM Cociorva, B Li, T Nomanbhoy, Q Li, A Nakamura, K Nakamura, ... Bioorganic & medicinal chemistry letters 21 (19), 5948-5951, 2011 | 29 | 2011 |
Tyzoon K. Nomanbhoy PublicationsVicinitas TherapeuticsVerified email at vicinitas.com
